3682-04-0 Usage
General Description
Naringenin triacetate is a chemical compound that is derived from naringenin, a flavonoid found in citrus fruits. It is a modified form of naringenin, in which three acetyl groups are attached to the hydroxyl groups of the molecule. Naringenin triacetate has been studied for its potential pharmaceutical applications, particularly for its anti-inflammatory, antioxidant, and anti-cancer properties. It has shown promising results in various preclinical studies, including its ability to inhibit the growth of cancer cells and reduce inflammation. Additionally, naringenin triacetate has also been investigated for its potential use in drug delivery systems, due to its improved solubility and stability compared to naringenin. Overall, naringenin triacetate is a compound of interest for its potential therapeutic and pharmaceutical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 3682-04-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,6,8 and 2 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 3682-04:
(6*3)+(5*6)+(4*8)+(3*2)+(2*0)+(1*4)=90
90 % 10 = 0
So 3682-04-0 is a valid CAS Registry Number.
3682-04-0Relevant articles and documents
Peracetylation of polyphenols under rapid and mild reaction conditions
Castro, Rosane Nora,Freire de Lima, Marco Edilson,Pitasse-Santos, Paulo,de Alcantara Pinto, Douglas Chaves,de Souza, Gabriela Alves
supporting information, (2022/01/31)
Structural modifications are an important tool for studying the properties of naturally occurring polyphenols. Regarding the preparation of acetyl esters, the presence of hydroxyl groups stabilized by intramolecular hydrogen bonds may pose an obstacle for
ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
-
Page/Page column 67; 76, (2019/12/28)
Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
